Moderna (NASDAQ:MRNA) Stock Price Down 3.4% on Insider Selling

Shares of Moderna, Inc. (NASDAQ:MRNA - Get Free Report) traded down 3.4% on Monday following insider selling activity. The stock traded as low as $120.38 and last traded at $120.72. 923,799 shares traded hands during mid-day trading, a decline of 77% from the average session volume of 4,102,888 shares. The stock had previously closed at $125.00.

Specifically, President Stephen Hoge sold 2,388 shares of Moderna stock in a transaction dated Thursday, February 29th. The stock was sold at an average price of $94.57, for a total transaction of $225,833.16. Following the transaction, the president now directly owns 1,515,898 shares in the company, valued at $143,358,473.86. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In related news, Director Noubar Afeyan sold 15,000 shares of the firm's stock in a transaction dated Wednesday, May 1st. The shares were sold at an average price of $110.92, for a total value of $1,663,800.00. Following the completion of the sale, the director now directly owns 2,026,931 shares in the company, valued at approximately $224,827,186.52. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, President Stephen Hoge sold 2,388 shares of the business's stock in a transaction that occurred on Thursday, February 29th. The stock was sold at an average price of $94.57, for a total value of $225,833.16. Following the transaction, the president now directly owns 1,515,898 shares in the company, valued at approximately $143,358,473.86. The disclosure for this sale can be found here. In the last three months, insiders sold 139,954 shares of company stock valued at $14,822,576. Company insiders own 15.20% of the company's stock.

Wall Street Analysts Forecast Growth

MRNA has been the subject of several research reports. Canaccord Genuity Group raised their price target on Moderna from $91.00 to $106.00 and gave the company a "hold" rating in a report on Friday. Needham & Company LLC reaffirmed a "hold" rating on shares of Moderna in a report on Thursday. William Blair reaffirmed a "market perform" rating on shares of Moderna in a research note on Monday, April 1st. Oppenheimer increased their price objective on shares of Moderna from $142.00 to $163.00 and gave the stock an "outperform" rating in a research note on Friday. Finally, HSBC restated a "reduce" rating and issued a $86.00 target price (up from $75.00) on shares of Moderna in a research report on Monday, February 26th. Two equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and six have issued a buy rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Hold" and a consensus price target of $129.55.

Moderna Trading Down 2.3 %

The stock has a 50 day moving average price of $105.05 and a 200 day moving average price of $94.48. The company has a debt-to-equity ratio of 0.04, a quick ratio of 3.91 and a current ratio of 4.03.

Moderna (NASDAQ:MRNA - Get Free Report) last posted its earnings results on Thursday, May 2nd. The company reported ($3.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($3.59) by $0.52. Moderna had a negative net margin of 115.82% and a negative return on equity of 20.10%. The business had revenue of $167.00 million for the quarter, compared to analysts' expectations of $93.26 million. During the same period in the prior year, the company posted $0.19 EPS. The business's revenue for the quarter was down 91.0% compared to the same quarter last year. As a group, sell-side analysts forecast that Moderna, Inc. will post -7.47 EPS for the current fiscal year.

Institutional Trading of Moderna

Several institutional investors and hedge funds have recently modified their holdings of MRNA. Vanguard Group Inc. grew its holdings in shares of Moderna by 22.6% in the fourth quarter. Vanguard Group Inc. now owns 33,907,072 shares of the company's stock worth $3,372,058,000 after purchasing an additional 6,248,623 shares during the last quarter. Norges Bank bought a new position in shares of Moderna during the fourth quarter valued at about $347,565,000. The Manufacturers Life Insurance Company boosted its holdings in shares of Moderna by 77.3% during the third quarter. The Manufacturers Life Insurance Company now owns 3,876,147 shares of the company's stock worth $400,367,000 after purchasing an additional 1,690,341 shares during the period. Wellington Management Group LLP grew its stake in shares of Moderna by 28.8% in the fourth quarter. Wellington Management Group LLP now owns 7,225,579 shares of the company's stock worth $718,584,000 after purchasing an additional 1,614,460 shares during the last quarter. Finally, Invesco Ltd. increased its holdings in Moderna by 19.8% during the 3rd quarter. Invesco Ltd. now owns 3,126,028 shares of the company's stock valued at $322,887,000 after purchasing an additional 517,683 shares during the period. Hedge funds and other institutional investors own 75.33% of the company's stock.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.